Clinical cancer proteomics: Promises and pitfalls

Journal of Proteome Research

Volumn 4, Issue 4, 2005, Pages 1213-1222

  Alaiya, Ayodele ^a   Al Mohanna, Mai ^a   Linder, Stig ^b  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cancer; Prognostic markers; Proteomics; Sample preparation; Serum

Indexed keywords

BIOLOGICAL MARKER; PROTEOME;

BREAST CANCER; CANCER; CANCER DIAGNOSIS; CONCENTRATION (PARAMETERS); DISEASE MARKER; FRACTIONATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION;

ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM PROTEINS; NEOPLASMS; PROTEOME; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 24044486897     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr050149f     Document Type: Review

References (108)

1. Weir, H. K.; Thun, M. J.; Hankey, B. F.; Ries, L. A.; Howe, H. L.; Wingo, P. A.; Jemal, A.; Ward, E.; Anderson, R. N.; Edwards, B. K. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and central. J. Natl. Cancer Inst. 2003, 95, 1276-1299.
2. Fox, R.; Hull, M. Ultrasound diagnosis of polycystic ovaries. Ann. N.Y. Acad. Sci. 1993, 687, 217-223.
3. Group, B. D. W. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69, 89-95.
4. Varadhachary, G. R.; Abbruzzese, J. L.; Lenzi, R. Diagnostic strategies for unknown primary cancer. Cancer 2004, 100, 1776-1785.
5. Schnitt, S. J. Traditional and newer pathologic factors. J. Natl. Cancer Inst. Monogr. 2001, 22-26.
6. Blackstock, W. P.; Weir, M. P. Proteomics: quantitative and physical mapping of cellular proteins. Trends Biotechnol. 1999, 17,121-127.
7. Alaiya, A. A.; Franzen, B.; Auer, G.; Linder, S. Cancer proteomics: from identification of novel markers to creation of artifical learning models for tumor classification [In Process Citation]. Electrophoresis 2000, 21, 1210-1217.
8. Anderson, L.; Seilhamer, J. A comparison of selected mRNA and protein abundancies in human liver. Electrophoresis 1997, 18, 533-537.
9. Alaiya, A.; Roblick, U.; Egevad, L.; Carlsson, A.; Franzen, B.; VoIz, D.; Huwendiek, S.; Linder, S.; Auer, G. Polypeptide expression in prostate hyperplasia and prostate adenocarcinoma. Anal. Cell Pathol. 2000, 21, 1-9.
10. Chen, G.; Gharib, T. G.; Wang, H.; Huang, C. C.; Kuick, R.; Thomas, D. G.; Shedden, K. A.; Misek, D. E.; Taylor, J. M.; Giordano, T. J.; Kardia, S. L.; Iannettoni, M. D.; Yee, J., Hogg, P. J.; Orringer, M. B.; Hanash, S. M.; Beer, D. G. Protein profiles associated with survival in lung adenocarcinoma. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 13537-13542.
11. Nishizuka, S.; Charboneau, L.; Young, L.; Major, S.; Reinhold, W. C.; Waltham, M.; Kouros-Mehr, H.; Bussey, K. J.; Lee, J. K.; Espina, V.; Munson, P. J.; Petricoin, E., 3rd; Liotta, L. A.; Weinstein, J. N. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 14229-14234.
12. Izzotti, A.; Bagnasco, M.; Cartiglia, C.; Longobardi, M.; De Flora, S. Proteomic analysis as related to transcriptome data in the lung of chromium(VI)-treated rats. Int. J. Oncol. 2004, 24, 1513-1522.
13. O'Farrell, P. H. High-resolution two-dimensional electrophoresis of proteins. J. Biol. Chem. 1975, 250, 4007-4021.
14. Klose, J. Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues. A novel approach to testing for induced point mutations in mammals. Humangenetik 1975, 26, 231-243.
15. Sanchez, J. C.; Wirth, P.; Jaccoud, S.; Appel, R. D.; Sarto, C.; Wilkins, M. R.; Hochstrasser, D. F. Simultaneous analysis of cyclin and oncogene expression using multiple monoclonal antibody immunoblots. Electrophoresis 1997, 18, 638-641.
16. Von Eggeling, F.; Gawriljuk, A.; Fiedler, W.; Ernst, G.; Claussen, U.; Klose, J.; Romer, I. Fluorescent dual colour 2D-protein gel electrophoresis for rapid detection of differences in protein pattern with standard image analysis software. Int. J. Mol. Med. 2001, 8, 373-377.
17. Tonge, R.; Shaw, J.; Middleton, B.; Rowlinson, R.; Rayner, S.; Young, J.; Pognan, F.; Hawkins, E.; Currie, I.; Davison, M. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics 2001, 1, 377-396.
18. Zhou, G.; Li, H.; DeCamp, D.; Chen, S.; Shu, H.; Gong, Y.; Flaig, M.; Gillespie, J. W.; Hu, N.; Taylor, P. R.; Emmert-Buck, M. R.; Liotta, L. A.; Petricoin, E. F., 3rd; Zhao, Y. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell. Proteomics 2002, 1, 117-124.
19. Mann, M.; Hojrup, P.; Roepstorff, P. Use of mass spectrometric molecular weight information to identify proteins in sequence databases. Biol. Mass Spectrom. 1993, 22, 338-345.
20. Mortz, E.; O'Connor, P. B.; Roepstorff, P.; Kelleher, N. L.; Wood, T. D.; McLafferty, F. W.; Mann, M. Sequence tag identification of intact proteins by matching tanden mass spectral data against sequence databases. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 8264-8267.
21. Yates, J. R., 3rd; Eng, J. K.; McCormack, A. L. Mining genomes; correlating tandem mass spectra of modified and unmodified peptides to sequences in nucleotide databases. Anal. Chem. 1995, 67, 3202-3210.
22. Pappin, D. J.; Hojrup, P.; Bleasby, A. J. Rapid identification of proteins by peptide-mass fingerprinting. Curr. Biol. 1993, 3, 327-332.
23. Washburn, M. P., Wolters, D.; Yates, J. R., 3rd. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol. 2001, 19, 242-247.
24. Gygi, S. P.; Han, D. K.; Gingras, A. C.; Sonenberg, N.; Aebersold, R. Protein analysis by mass spectrometry and sequence database searching: tools for cancer research in the post-genomic era. Electrophoresis 1999, 20, 310-319.
25. Wall, D. B.; Kachman, M. T.; Gong, S.; Hinderer, R.; Parus, S.; Misek, D. F.; Hanash, S. M.; Lubman, D. M. Isoelectric focusing nonporous RP HPLC: a two-dimensional liquid-phase separation method for mapping of cellular proteins with identification using MALDI-TOF mass spectrometry. Anal. Chem. 2000, 72, 1099-1111.
26. MacBeath, G.; Schreiber, S. L. Printing proteins as microarrays for high-throughput function determination. Science 2000, 289, 1760-1763.
27. Haab, B. B.; Dunham, M. J.; Brown, P. O. Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol. 2001, 2, RESEARCH0004.
28. Predki, P. F. Functional protein microarrays: ripe for discovery. Curr. Opin. Chem. Biol. 2004, 8, 8-13.
29. Kusnezow, W.; Hoheisel, J. D. Antibody microarrays: promises and problems. Biotech. Suppl. 2002, 14-23.
30. Fung, E. T.; Thulasiraman, V.; Weinberger, S. R.; Dalmasso, E. A. Protein biochips for differential profiling. Curr. Opin. Biotechnol. 2001, 12, 65-69.
31. Franzen, B.; Linder, S.; Okuzawa, K.; Kato, H.; Auer, G. Nonenzymatic extraction of cells from clinical tumor material for analysis of gene expression by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 1993, 14, 1045-1053.
32. Ahram, M.; Flaig, M. J.; Gillespie, J. W.; Duray, P. H.; Linehan, W. M.; Ornstein, D. K.; Niu, S.; Zhao, Y.; Petricoin, E. F., 3rd; Emmert-Buck, M. R. Evaluation of ethanol-fixed, paraffin-embedded tissues for proteomic applications. Proteomics 2003, 3, 413-421.
33. Yu, B.; Li, S. Y.; An, P.; Zhang, Y. N.; Liang, Z. J.; Yuan, S. J.; Cai, H. Y. Comparative study of proteome between primary cancer and hepatic metastatic tumor in colorectal cancer. World J. Gastroenteml. 2004, 10, 2652-2656.
34. Page, M. J.; Amess, B.; Townsend, R. R.; Parekh, R.; Herath, A.; Brusten, L.; Zvelebil, M. J.; Stein, R. C.; Waterfield, M. D.; Davies, S. C.; O'Hare, M. J. Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 12589-12594.
35. Emmert-Buck, M. R.; Bonner, R. F.; Smith, P. D.; Chuaqui, R. F.; Zhuang, Z.; Goldstein, S. R.; Weiss, R. A.; Liotta, L. A. Laser capture microdissection. Science 1996, 274, 998-1001.
36. Wulfkuhle, J. D.; Sgroi, D. C.; Krutzsch, H.; McLean, K.; McGarvey, K.; Knowlton, M.; Chen, S.; Shu, H.; Sahin, A.; Kurek, R.; Wallwiener, D.; Merino, M. J.; Petricoin, E. F., 3rd; Zhao, Y.; Steeg, P. S. Proteomics of human breast ductal carcinoma in situ. Cancer Res. 2002, 62, 6740-6749.
37. Craven, R. A.; Totty, N.; Harnden, P.; Selby, P. J.; Banks, R. E. Laser capture microdissection and two-dimensional polyacrylamide gel electrophoresis: evaluation of tissue preparation and sample limitations. Am. J. Pathol. 2002, 160, 815-822.
38. Knezevic, V.; Leethanakul, C.; Bichsel, V. E.; Worth, J. M.; Prabhu, V. V.; Gutkind, J. S.; Liotta, L. A.; Munson, P. J.; Petricoin, E. F., 3rd; Krizman, D. B. Proteomic profiling of the cancer microenvironment by antibody arrays. Proteomics 2001, 1, 1271-1278.
39. 18O isotopic labeling. J. Proteome Res. 2004, 3, 604-612.
40. Ornstein, D. K.; Gillespie, J. W.; Paweletz, C. P.; Duray, P. H.; Herring, J.; Vocke, C. D.; Topalian, S. L., Bostwick, D. G., Linehan, W. M.; Petricoin, E. F., 3rd and Emmert-Buck, M. R. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 2000, 21, 2235-2242.
41. Lawrie, L. C.; Curran, S.; McLeod, H. L.; Fothergill, J. E.; Murray, G. I. Application of laser capture microdissection and proteomics in colon cancer. Mol. Pathol. 2001, 54, 253-258.
42. Jones, M. B.; Krutzsch, H.; Shu, H.; Zhao, Y.; Liotta, L. A.; Kohn, E. C.; Petricoin, E. F., 3rd. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2002, 2, 76-84.
43. Shekouh, A. R.; Thompson, C. C.; Prime, W.; Campbell, F.; Hamlett, L; Herrington, C. S.; Lemoine, N. R.; Crnogorac-Jurcevic, T.; Buechler, M. W.; Friess, H.; Neoptolemos, J. P.; Pennington, S. R.; Costello, E. Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics 2003, 3, 1988-2001.
44. Franzen, B.; Auer, G.; Alaiya, A. A.; Eriksson, E.; Uryu, K.; Hirano, T.; Okuzawa, K.; Kalo, H.; Linder, S. Assessment of homogeneity in polypeptide expression shows highly variable expression in high malignant breast carcinomas. Int. J. Cancer 1996, 69, 408-414.
45. Roblick, U. J.; Hirschberg, D.; Habermann, J. K.; Palmberg, C.; Becker, S.; Kruger, S.; Gustafsson, M.; Bruch, H. P.; Franzen, B.; Ried, T.; Bergmann, T.; Auer, G.; Jornvall, H. Sequential proteome alterations during genesis and progression of colon cancer. Cell. MoI. Life Sci. 2004, 61, 1246-1255.
46. Kerbel, R. S.; Waghorne, C.; Korczak, B.; Lagarde, A.; Breitman, M. L. Clonal dominance of primary tumors by metastatic cells; genetic analysis and biological implications. Cancer Surveys 1988, 7, 597-630.
47. Celis, A.; Rasmussen, H. H.; Celis, P.; Basse, B.; Lauridsen, J. B.; Ratz, G.; Hein, B.; Ostergaard, M.; Wolf, H.; Orntoft, T.; Celis, J. E. Short-term culturing of low-grade superficial bladder transitional cell carcinomas leads to changes in the expression levels of several proteins involved in key cellular activities. Electrophoresis 1999, 20, 355-361.
48. Fresno Vara, J. A.; Casado, E.; de Castro, J.; Cejas, P.; Belda-Iniesta, C.; Gonzalez-Baron, M. PI3K/Akt signaling pathway and cancer. Cancer Treat. Rev. 2004, 30, 193-204.
49. David, O.; Jett, J.; LeBeau, H.; Dy, G.; Hughes, J.; Friedman, M.; Brody, A. R. Phospho-Akt overexpression in nonsmall cell lung cancer confers significant stage-independent survival disadvantage. Clin. Cancer Res. 2004, 10, 6865-6871.
50. Celis, J. E.; Gromov, P. Proteomics in translational cancer research: toward an integrated approach. Cancer Cell. 2003, 3, 9-15.
51. Hanash, S. Disease proteomics. Nature 2003, 422, 226-232.
52. Hondermarck, H.; Vercoutter-Edouart, A. S.; Revillion, F.; Lemoine, J.; el-Yazidi-Belkoura, L; Nurcombe, V.; Peyrat, J. P. Proteomics of breast cancer for marker discovery and signal pathway profiling. Proteomics 2001, 1, 1216-1232.
53. Celis, J. E.; Gromova, I.; Moreira, J. M.; Cabezon, T.; Gromov, P. Impact of proteomics on bladder cancer research. Pharmacogenomics 2004, 5, 381-394.
54. Ostergaard, M.; Rasmussen, H. H.; Nielsen, H. V.; Vorum, H., Orntoft, T. F., Wolf, H.; Celis, J. E. Proteome profiling of bladder squamous cell carcinomas: identification of markers that define their degree of differentiation. Cancer Res. 1997, 57, 4111-4117.
55. Moreira, J. M.; Gromov, P.; Celis, J. E. Expression of the tumor suppressor protein 14-3-3 sigma is down-regulated in invasive transitional cell carcinomas of the urinary bladder undergoing epithelial-to-mesenchymal transition. Mol Cell Proteomics 2004, 3, 410-419.
56. Celis, J. E.; Celis, P.; Ostergaard, M.; Basse, B.; Lauridsen, J. B.; Ratz, G.; Rasmussen, H. H.; Orntoft, T. F.; Hein, B.; Wolf, H.; Celis, A. Proteomics and immunohistochemistry define some of the steps involved in the squamous differentiation of the bladder transitional epithelium: a novel strategy for identifying metaplastic lesions. Cancer Res. 1999, 159, 3003-3009.
57. Kageyama, S.; Isono, T.; Iwaki, H.; Wakabayashi, Y.; Okada, Y.; Kontani, K.; Yoshimura, K; Terai, A.; Arai, Y.; Yoshiki, T. Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin. Chem. 2004, 50, 857-866.
58. Muller, M. Telomerase: its clinical relevance in the diagnosis of bladder cancer. Oncogene 2002, 21, 650-655.
59. Glas, A. S.; Roos, D.; Deutekom, M.; Zwinderman, A. H.; Bossuyt, P. M.; Kurth, K. H. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J. Urol. 2003, 169, 1975-1982.
60. Dey, P. Urinary markers of bladder carcinoma. Clin, Chim. Acta 2004, 340, 57-65.
61. Rasmussen, H. H.; Orntoft, T. F.; Wolf, H.; Celis, J. E. Towards a comprehensive database of proteins from the urine of patients with bladder cancer. J. Urol. 1996, 155, 2113-2119.
62. Pieper, R.; Gatlin, C. L.; McGrath, A. M.; Makusky, A. J.; Mondal, M.; Seonarain, M.; Field, E.; Schatz, C. R.; Estock, M. A.; Ahmed, N.; Anderson, N. G.; Steiner, S. Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics 2004, 4, 1159-1174.
63. Vlahou, A.; Schellhammer, P. F.; Mendrinos, S.; Patel, K.; Kondylis, F. L.; Gong, L.; Nasim, S.; Wright, G. L., Jr. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am. J. Pathol. 2001, 158, 1491-1502.
64. Franzén, B.; Linder, S.; Uryu, K.; Alaiya, A. A.; Hirano, T.; Kato, K.; Auer, G. Expression of tropomyosin isoforms in benign and malignant human breast lesions. Br. J. Cancer 1996, 73, 909-913.
65. Franzén, B.; Auer, G.; Alaiya, A. A.; Eriksson, E.; Uryu, K.; Hirano, T.; Okuzawa, K.; Linder, S. Analysis of polypeptide expression in benign and malignant human breast lesions: down-regulation of cytokeratins. Br. J. Cancer 1996, 73, 1632-1638.
66. Bini, L.; Magi, B.; Marzocchi, B.; Arcuri, F.; Tripodi, S.; Cintorino, M.; Sanchez, J. C.; Frutiger, S.; Hughes, G.; Pallini, V.; Hochstrasser, D. F.; Tosi, P. Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis 1997, 18, 2832-2841.
67. Bergman, A. C.; Benjamin, T.; Alaiya, A.; Waltham, M.; Sakaguchi, K.; Franzen, B.; Linder, S.; Bergman, T.; Auer, G.; Appella, E.; Wirth, P. J.; Jornvall, H. Identification of gel-separated tumor marker proteins by mass spectrometry. Electrophoresis 2000, 21, 679-686.
68. Somiari, R. I.; Sullivan, A.; Russell, S.; Somiari, S.; Hu, H.; Jordan, R.; George, A.; Katenhusen, R.; Buchowiecka, A.; Arciero, C.; Brzeski, H.; Hooke, J.; Shriver, C. High-throughput proteomic analysis of human infiltrating ductal carcinoma of the breast. Proteomics 2003, 3, 1863-1873.
69. Dwek, M. V.; Alaiya, A. A. Proteome analysis enables separate clustering of normal breast, benign breast and breast cancer tissues. Br. J. Cancer 2003, 89, 305-307.
70. Alexander, H.; Stegner, A. L.; Wagner-Mann, C.; Du Bois, G. C.; Alexander, S.; Sauter, E. R. Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. Clin. Cancer Res. 2004, 20, 7500-7510.
71. Okuzawa, K.; Franzen, B.; Lindholm, J.; Linder, S.; Hirano, T.; Bergman, T.; Ebihara, Y.; Kato, H.; Auer, G. Characterization of gene expression in clinical lung cancer materials by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 1994, 15, 382-390.
72. Hirano, T.; Gong, Y.; Yoshida, K.; Kato, Y.; Yashima, K.; Maeda, M.; Nakagawa, A.; Fujioka, K.; Ohira, T.; Ikeda, N.; Ebihara, Y.; Auer, G.; Kato, H. Usefulness of TA02 (napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adenocar-cinoma. Lung Cancer 2003, 41, 155-162.
73. Ueno, T.; Linder, S.; Elmberger, G. Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. Br. J. Cancer 2003, 88, 1229-1233.
74. Ueno, T.; Linder, S.; Na, C. L.; Rice, W. R.; Johansson, J.; Weaver, T. E. Processing of pulmonary surfactant protein B by napsin and cathepsin H. J Biol. Chem. 2004, 279, 16178-16184.
75. Chen, G.; Gharib, T. G.; Huang, C. C.; Thomas, D. G.; Shedden, K. A.; Taylor, J. M.; Kardia, S. L.; Misek, D. E.; Giordano, T. J.; lannettoni, M. D.; Orringer, M. B.; Hanash, S. M.; Beer, D. G. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin. Cancer Res. 2002, 8, 2298-2305.
76. Yanagisawa, K.; Shyr, Y.; Xu, B. J.; Massion, P. P.; Larsen, P. H.; White, B. C.; Roberts, J. R.; Edgerton, M.; Gonzalez, A.; Nadaf, S.; Moore, J. H.; Caprioli, R. M.; Carbone, D. P. Proteomic patterns of tumour subsets in nonsmall-cell lung cancer. Lancet 2003, 362, 433-439.
77. Lawrence, W. D. The borderland between benign and malignant surface epithelial ovarian tumors. Current controversy over the nature and nomenclature of "borderline" ovarian tumors. Cancer 1995, 76, 2138-2142.
78. Maiya, A. A.; Franzen, B.; Fujioka, K.; Moberger, B.; Schedvins, K.; Silfversvard, C.; Linder, S.; Auer, G. Phenotypic analysis of ovarian carcinoma: polypeptide expression in benign, borderline e.nd malignant tumors. Int. J. Cancer 1997, 73, 678-683.
79. Alaiya, A. A.; Franzen, B.; Hagman, A.; Silfversward, C.; Moberger, I!.; Linder, S.; Auer, G. Classification of human ovarian tumors using multivariate data analysis of polypeptide expression patterns. Int. J. Cancer 2000, 86, 731-736.
80. Alaiya, A. A.; Franzen, B.; Hagman, A.; Dysvik, B.; Roblick, U. J.; Decker, S.; Moberger, B.; Auer, G.; Linder, S. Molecular classification of borderline ovarian tumors using hierarchical cluster E.nalysis of protein expression profiles. Int. J. Cancer 2002, 98, 895-899.
81. Friedman, D. B.; Hill, S.; Keller, J. W.; Merchant, N. B.; Levy, S. E.; Coffey, R. J.; Caprioli, R. M. Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 2004, 4, 793-811.
82. Voss, T.; Ahorn, H.; Haberl, P.; Dohner, H.; Wilgenbus, K. Correlation of clinical data with proteomics profiles in 24 patients with B-cell chronic lymphocytic leukemia. Int. J. Cancer 2001, 91, 180-186.
83. Bisca, A.; D'Ambrosio, C.; Scaloni, A.; Puglisi, F.; Aprile, G.; Piga, A.; Zuiani, C.; Bazzocchi, M.; Di Loreto, C.; Paron, I.; Tell, G.; Damante, G. Proteomic evaluation of core biopsy specimens from breast lesions. Cancer Lett. 2004, 204, 79-86.
84. Bast, R. C., Jr.; Ravdin, P.; Hayes, D. F.; Bates, S.; Fritsche, H., Jr.; Jassup, J. M.; Kemeny, N.; Locker, G. Y.; Mennel, R. G.; Somerfield, M. R. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 2001, 19, 1865-1878.
85. Ross, J. S.; Linette, G. P.; Stec, J.; Clark, E.; Ayers, M.; Leschly, N.; Symmans, W. F.; Hortobagyi, G. N.; Pusztai, L. Breast cancer tiomarkers and molecular medicine: part II. Expert Rev. Mol. Diagn. 2004, 4, 169-188.
86. Kramer, G.; Erdal, H.; Mertens, H. J.; Nap, M.; Mauermann, J.; Steiner, G.; Marberger, M.; Biven, K.; Shoshan, M. C.; Linder, S. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res. 2004, 64, 1751-1756.
87. Bjorklund, B. Tissue polypeptide antigen (TPA): Biology, biochemistry, improved assay methodology, clinical significance in cincer and other conditions, and future outlook. Antibiot. Chemother. 1978, 22, 16-31.
88. Weber, K.; Osborn, M.; Moll, R.; Wiklund, B.; Luning, B. Tissue polypeptide antigen (TPA) is related to the nonepidermal keratins 8, 18 and 19 typical of simple and nonsquamous epithelia: re-evaluation of a human tumor marker. Embo J. 1984, 3, 2707-2714.
89. Stieber, P.; Hasholzner, U.; Bodenmuller, H.; Nagel, D.; Sunder-Plassmann, L.; Dienemann, H.; Meier, W.; Fateh-Moghadam, A. CYFRA 21-1. Anew marker in lung cancer. Cancer 1993, 72, 707-713.
90. Ahmed, N.; Barker, G.; Oliva, K.; Garfin, D.; Talmadge, K.; Georgiou, H.; Quinn, M.; Rice, G. An approach to remove albumin for the proteomic analysis of low abundance biomarkers in human serum. Proteomics 2003, 3, 1980-1987.
91. Pieper, R.; Su, Q.; Gatlin, C. L.; Huang, S. T.; Anderson, N. L.; Steiner, S. Multicomponent immunoaffinity subtraction chromatography: an innovative step towards a comprehensive survey of the human plasma proteome. Proteomics 2003, 3, 422-432.
92. Solassol, J.; Marin, P.; Demettre, E.; Rouanet, P.; Bockaert, J.; Maudelonde, T.; Mange, A. Proteomic detection of prostate-specific antigen using a serum fractionation procedure: potential implication for new low-abundance cancer biomarkers detection. Anal. Biochem. 2005, 338, 26-31.
93. Poon, T. C.; Johnson, P. J. Proteome analysis and its impact on the discovery of serological tumor markers. Clin. Chim. Acta 2001, 313, 231-239.
94. Rodriguez-Pineiro, A. M.; Ayude, D.; Rodriguez-Berrocal, F. J.; Paez de la Cadena, M. Concanavalin A chromatography coupled to two-dimensional gel electrophoresis improves protein expression studies of the serum proteome. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2004, 803, 337-343.
95. Petricoin, E. F.; Ardekani, A. M.; Hitt, B. A.; Levine, P. J.; Fusaro, V. A.; Steinberg, S. M.; Mills, G. B.; Simone, C.; Fishman, D. Á.; Kohn, E. C.; Liotta, L. A. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359, 572-577.
96. Nature, c.i. Proteomic diagnostics tested. Nature 2004, 429, 487.
97. Diamandis, E. P. OvaCheck: doubts voiced soon after publication. Nature 2004, 430, 611.
98. Sorace, J. M.; Zhan, M. A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinform. 2003, 4, 24.
99. Baggerly, K. A.; Morris, J. S.; Coombes, K. R. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 2004, 20, 777-785.
100. Rai, A. J.; Zhang, Z.; Rosenzweig, J.; Shih Ie, M.; Pham, T.; Fung, E. T.; Sokoll, L. J.; Chan, D. W. Proteomic approaches to tumor marker discovery. Arch. Pathol. Lab. Med. 2002, 126, 1518-1526.
101. Koopmann, J.; Zhang, Z.; White, N.; Rosenzweig, J.; Fedarko, N.; Jagannath, S.; Canto, M. I.; Yeo, C. J.; Chan, D. W.; Goggins, M. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin. Cancer Res. 2004, 10, 860-868.
102. Pearl, D. C. Proteomic patterns in serum and identification of ovarian cancer. Lancet 2002, 360, 169-170; author reply 170-171.
103. Rockhill, B. Proteomic patterns in serum and identification of ovarian cancer. Lancet 2002, 360, 169; author reply 170-171.
104. Ribom, D.; Westman-Brinkmalm, A.; Smits, A.; Davidsson, P. Elevated levels of alpha-2-Heremans-Schmid glycoprotein in CSF of patients with low-grade gliomas. Tumour Biol. 2003, 24, 94-99.
105. Zheng, P. P.; Luider, T. M.; Pieters, R.; Avezaat, C. J.; van den Bent, M. J.; Sillevis Smitt, P. A.; Kros, J. M. Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors. J. Neuropathol. Exp. Neurol. 2003, 62, 855-862.
106. Paweletz, C. P.; Trock, B.; Pennanen, M.; Tsangaris, T.; Magnant, C.; Liotta, L. A.; Petricoin, E. F., 3rd. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis. Markers 2001, 17, 301-307.
107. Sauter, E. R.; Zhu, W.; Fan, X. J.; Wassell, R. P.; Chervoneva, I.; Du Bois, G. C. Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer. Br. J. Cancer 2002, 86, 1440-1443.
108. Grizzle, W. E.; Adam, B. L.; Bigbee, W. L.; Conrads, T. P.; Carroll, C.; Feng, Z.; Izbicka, E.; Jendoubi, M.; Johnsey, D.; Kagan, J.; Leach, R. J.; McCarthy, D. B.; Semmes, O. J.; Srivastava, S.; Srivastava, S.; Thompson, I. M.; Thornquist, M. D.; Verma, M.; Zhang, Z.; Zou, Z. Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer. Dis. Markers 2003, 19, 185-195.